Additionally, PIK3CA is one of the most commonly mutated oncogenes in human cancers [14], and PIK3CA mutations have been shown to be a favorable factor for the clinical outcomes of PI3K inhibitors [57]. This evidence concerns the gene PIK3CA and cancer.